Top Markets
Coin of the day
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
Hisse Senetlerindeki Sıralama #30071
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Hisse Fiyatı
$0.00775813
Piyasa Değeri
$18.35M
Değişim (1 gün)
-8.33%
Değişim (1 yıl)
-51.93%
Ülke
AU
Ticaret Radiopharm Theranostics Limited (RAD)

Kategori

Radiopharm Theranostics Limited (RAD) için P/S oranı
2026 itibarıyla P/S oranı TTM: 0
Radiopharm Theranostics Limited şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/S oranı 0 idi.
Radiopharm Theranostics Limited için P/S oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/S oranı
Yıl P/S Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/S oranı
Şirket P/S Oranı P/S Oranı Farkı Ülke
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
4.74 -
BE